PHARMAC is seeking feedback on a proposal to list a range of orthopaedic implants and associated products ('Orthopaedic Products') in Part III of Section H of the Pharmaceutical Schedule from
Consultation closes at
What would the effect be
From
The Agreement would not be for sole supply, with DHBs continuing to be able to purchase other suppliers' brands of orthopaedic products.
The Agreement would supersede any existing DHB contracts with
As part of the Agreement,
Who we think will be interested
Suppliers and wholesalers
DHB Staff: Orthopaedic Surgeons
Sterile Services personnel
Perioperative personnel
Procurement and supply chain personnel
About orthopaedic products
The orthopaedic products under this agreement are used to treat bone related injury or disease through surgical intervention. The associated products relate to the instruments or products required for preparation and/or adherence at the implant site, or physical manipulation of the implants required when undertaking the surgery.
Why we're proposing this
In 2016 PHARMAC issued a Request for Proposals ('RFP') for orthopaedic implants and associated products.
This RFP was for non-exclusive national agreements for listing in the Pharmaceutical Schedule.
PHARMAC has been working with suppliers who responded to the RFP to seek provisional agreements and this is the final agreement PHARMAC intend to enter into in this category as a result of that RFP process.
Details about our proposal
PHARMAC has entered into a provisional Agreement with
To provide feedback
Send us an email: maree.hodgson@pharmac.govt.nz by
All feedback received before the closing date will be considered by PHARMAC's Board (or its delegate) prior to making a decision on this proposal.
Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.
We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.
Contact:
Tel: 021 863 342
(C) 2020 Electronic News Publishing, source